The Lancet Public Health quasi-experimental study (n approximately 4500 births, pre-post comparison with matched Michigan cities) demonstrates that Rx Kids unconditional cash—$1500 prenatal plus $500 monthly infancy—reversed rising preterm and low-birthweight trends in Flint after 2024 launch, yielding 18% and 27% reductions respectively alongside 29% fewer NICU admissions. As an observational design rather than RCT, residual confounding remains possible despite controls, and potential conflicts exist given lead author Sumit Agarwal’s Michigan affiliations and co-author Mona Hanna’s dual role as Rx Kids director. Beyond the reported metrics, the findings directly address lingering epigenetic and stress-mediated harms from the 2014–2015 water crisis, where lead exposure already elevated baseline risks; cash appears to interrupt the poverty-pathogen pathway by boosting prenatal care uptake, reducing smoking, and stabilizing housing—outcomes previously shown in smaller pilots but rarely at population scale. Comparable evidence appears in the 2021 Baby’s First Years RCT (n=1000 low-income mothers) documenting modest cognitive gains from similar monthly transfers, and in a 2023 observational analysis of expanded EITC payments linking $1000 annual boosts to 2–3% drops in adverse birth outcomes across 14 states. Collectively these indicate that timing transfers to the perinatal window outperforms downstream clinical interventions alone, with millions in avoided NICU costs already realized in Flint. Policy implications extend nationally: scaling Rx Kids to other post-industrial cities could recalibrate maternal-health spending away from siloed medical models toward upstream economic remediation, provided future RCTs confirm generalizability.